Release Date: September 30, 2024
Expiration Date: September 30, 2025
Activity Overview
Antibody-drug conjugates (ADCs) aim to provide the same level of antitumor cytotoxicity as chemotherapy while reducing off-target effects. Recently, the HER2-targeting ADC trastuzumab deruxtecan (T-DXd) has gained approval for patients with HER2-mutated non–small cell lung cancer (NSCLC). T-DXd is currently being evaluated in patients with HER2 overexpression. Additional investigations into ADCs targeting Trop2 are also underway.
This educational activity is an archive of the live symposium held in September 2024.
Target Audience
This educational activity is directed toward a global audience of community and academic medical oncologists and pathologists interested in the treatment and management of NSCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Examine the mechanistic rationale for targeting HER2 and TROP2 in the management of lung cancer with antibody-drug conjugates
- Explain clinical guidance and therapeutic strategies in the management of lung cancer using selected antibody-drug conjugates
- Analyze clinical evidence and ongoing trials assessing antibody-drug conjugates in lung cancer targeting specific ligands
- Recommend appropriate strategies for monitoring and management of potential adverse effects associated with HER2- and TROP2-directed antibody-drug conjugates in the management of lung cancer
Jacob Sands, MD
Assistant Professor
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Disclosures: Grant/Research Support: Amgen, Harpoon Therapeutics; Consultant: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Gilead Sciences, Medtronic, Lilly, PharmaMar, Sanofi.
Myung-Ju Ahn, MD
Professor
Division of Hemato-Oncology
Department of Medicine
Samsung Medical Center
Sungkyunkwan University School of Medicine
Seoul, South Korea
Disclosures: Consultant: Alpha Pharmaceuticals, Amgen, AstraZeneca, Daiichi Sankyo, Genexine, MSD, Roche, Takeda; Speakers’ Bureau: Amgen, AstraZeneca, Daiichi Sankyo, Merck, MSD, Roche, Takeda; Honoraria: Amgen, AstraZeneca, Daiichi Sankyo, Merck, MSD, Roche, Takeda.
Aaron Lisberg, MD
Assistant Professor of Clinical Medicine
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA
Disclosures: Grant/Research Support: AstraZeneca, Calithera Biosciences, Daiichi Sankyo, Dracen Pharmaceuticals, Duality Biologics, eFFECTOR Therapeutics, WindMIL Therapeutics; Consultant: Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, G1 Therapeutics, Gilead Sciences, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Lilly, Molecular Axiom, MorphoSys, Novartis, Novocure, Oncocyte, Pfizer, Regeneron, Sanofi; Stock (Spouse): Boston Scientific; Employment (Spouse): Boston Scientific.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
